Astria Therapeutics, Inc.
ATXS
$7.49
-$0.04-0.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 37.47M | 35.69M | 34.78M | 32.54M | 30.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 131.42M | 124.40M | 111.56M | 100.97M | 92.19M |
| Operating Income | -131.42M | -124.40M | -111.56M | -100.97M | -92.19M |
| Income Before Tax | -116.92M | -108.04M | -94.26M | -100.04M | -93.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -116.92 | -108.04 | -94.26 | -100.04 | -93.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -116.92M | -108.04M | -94.26M | -100.04M | -93.24M |
| EBIT | -131.42M | -124.40M | -111.56M | -100.97M | -92.19M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.02 | -1.88 | -1.68 | -2.09 | -2.30 |
| Normalized Basic EPS | -1.26 | -1.17 | -1.05 | -1.05 | -1.18 |
| EPS Diluted | -2.02 | -1.88 | -1.68 | -2.09 | -2.30 |
| Normalized Diluted EPS | -1.26 | -1.17 | -1.05 | -1.05 | -1.18 |
| Average Basic Shares Outstanding | 231.85M | 230.33M | 224.62M | 203.09M | 173.31M |
| Average Diluted Shares Outstanding | 231.85M | 230.33M | 224.62M | 203.09M | 173.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |